Correlation Between Virpax Pharmaceuticals and Sonnet Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virpax Pharmaceuticals and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Sonnet Biotherapeutics.

Diversification Opportunities for Virpax Pharmaceuticals and Sonnet Biotherapeutics

0.7

Correlation Coefficient

Virpax Pharmaceuticals  Sonnet Biotherapeutics

Poor diversification

The 3 months correlation between Virpax and Sonnet is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and Sonnet Biotherapeutics

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to generate 1.41 times more return on investment than Sonnet Biotherapeutics. However, Virpax Pharmaceuticals is 1.41 times more volatile than Sonnet Biotherapeutics Holdings. It trades about -0.01 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.25 per unit of risk. If you would invest  50.00  in Virpax Pharmaceuticals on October 5, 2024 and sell it today you would lose (12.00) from holding Virpax Pharmaceuticals or give up 24.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Virpax Pharmaceuticals  vs.  Sonnet Biotherapeutics Holding

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Virpax Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Sonnet Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Virpax Pharmaceuticals and Sonnet Biotherapeutics

The main advantage of trading using opposite Virpax Pharmaceuticals and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.

The idea behind Virpax Pharmaceuticals and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.